T6255

Bromosporine is a broad spectrum inhibitor for bromodomains for BRD2/4/9 and CECR2 (IC50: 0.41/0.29/0.122/0.017 μM), respectively.

DSM705 hydrochloride is a potent antimalarial compound and a pyrrole-based inhibitor of dihydroorotate dehydrogenase (DHODH).DSM705 hydrochloride shows nanomolar effects against PlasmodiumDHODH and Plasmodium parasites and does not inhibit mammalian DHODH.

ANEB-001 is an orally active CB1 inhibitor suitable for studies on acute cannabinoid intoxication.

Ozanimod hydrochloride (RPC-1063 hydrochloride) is an orally available, selective and potent sphingosine 1-phosphate (S1P) receptor modulator that shows high affinity for S1P1 and S1P5.Ozanimod has potential anticancer activity and can be used in the study of multiple sclerosis (MS), ulcerative multiple sclerosis (UMS), and other diseases. (MS), ulcerative colitis, coronavirus infections and myelodysplasia.

JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK, targeting critical pathways in autoimmune diseases. The simultaneous inhibition of the BTK/JAK3 signaling pathway exerts a synergistic effect, making JAK3/BTK-IN-4 a promising therapeutic candidate for JAK3 kinase and/or BTK-related diseases.

PPARγ phosphorylation inhibitor 1 (Compound 10) is an effective PPARγ agonist (IC50=24 nM) that inhibits CDK5-mediated PPARγ Ser273 phosphorylation (IC50=160 nM) and exhibits antidiabetic activity.

MMP-2/9-IN-1 (Compound 4a) is a potent dual inhibitor of MMP-2 (IC50: 56 nM) and MMP-9 (IC50: 38 nM), leading to DNA fragmentation.

JAK-IN-23 is an orally active dual JAK/STAT and NF-κB inhibitor that inhibits JAK1 (IC50: 8.9 nM), JAK2 (IC50: 15 nM), and JAK3 (IC50: 46.2 nM). It exhibits strong anti-inflammatory effects and can reduce the release of various pro-inflammatory factors. JAK-IN-23 can be used to study inflammatory bowel disease (IBD).

CSF1R-IN-14, an isoindolinone derivative compound, is a potent inhibitor of CSF1R. CSF1R-IN-14 has potential for cancer disease research.

FAAH-IN-5 (Compound 7) is a relatively selective, irreversible inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 10.5 nM and exhibits low permeability in PAMPA (parallel artificial membrane permeability assay).

TGFβRI-IN-4 is a potent, orally active TGFβ receptor type I kinase (TGFβRI) inhibitor that targets ALK5 (IC50: 44 nM) and NIH3T3 (IC50: 42.5 nM), inhibiting tumor growth and weight in a xenograft tumor model.